2011
DOI: 10.1128/jb.06248-11
|View full text |Cite
|
Sign up to set email alerts
|

Characterization of Type II and III Restriction-Modification Systems from Bacillus cereus Strains ATCC 10987 and ATCC 14579

Abstract: The genomes of two Bacillus cereus strains (ATCC 10987 and ATCC 14579) have been sequenced. Here, we report the specificities of type II/III restriction (R) and modification (M) enzymes. Found in the ATCC 10987 strain, BceSI is a restriction endonuclease (REase) with the recognition and cut site CGAAG 24-25/27-28. BceSII is an isoschizomer of AvaII (G/GWCC). BceSIII cleaves at ACGGC 12/14. The BceSIII C terminus resembles the catalytic domains of AlwI, MlyI, and Nt.BstNBI. BceSIV is composed of two subunits an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
33
0

Year Published

2012
2012
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 26 publications
(34 citation statements)
references
References 46 publications
1
33
0
Order By: Relevance
“…cereus ATCC 10987 had previously been examined by Xu et al (25), who determined recognition sequences for four Type II and III REases and one orphan MTase by traditional methods. However, the sites of methylation for the Type II and III MTases were not determined and several other MTases were not examined including that in the Type I system (BCE_0839-BCE_0842) and a Type II MTase (BCE_0392) that was reported to be inactive (25). However, when we cloned this MTase and checked its activity, it was clearly a promiscuous m6 A MTase, which we have now named M.BceSVII (Supplementary Figure S9 and Table 1).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…cereus ATCC 10987 had previously been examined by Xu et al (25), who determined recognition sequences for four Type II and III REases and one orphan MTase by traditional methods. However, the sites of methylation for the Type II and III MTases were not determined and several other MTases were not examined including that in the Type I system (BCE_0839-BCE_0842) and a Type II MTase (BCE_0392) that was reported to be inactive (25). However, when we cloned this MTase and checked its activity, it was clearly a promiscuous m6 A MTase, which we have now named M.BceSVII (Supplementary Figure S9 and Table 1).…”
Section: Resultsmentioning
confidence: 99%
“…It is important to note that while cloning the individual MTase genes showed five to be active only four seem to be active in the genome. M.BceSV, a multi-specific MTase characterized in the previous study by cloning and overexpression (25) is encoded on a prophage and does not show detectable activity in the native host genome. In addition to the m6 A and m4 C MTases mentioned earlier, our analysis indicated two more motifs that are likely modified by one or more of the predicted m5 C MTases in the B. cereus genome, as 179 of the 524 unassigned hits fell into two categories.…”
Section: Resultsmentioning
confidence: 99%
“…Therefore BCE_0392 might modify sequences that are not recognized by these REase, and new techniques like single-molecule DNA sequencing other than restriction analysis using commercialized REases should be useful in identifying the sequence specificity of BCE_0392 [29]. DNA nicking-associated concatenation activity was also detected for BCE_0392 in vivo [15], suggesting that this ParB-Methyltransferase might participate in phage DNA replication or phage packaging, since BCE_0392 was located in a prophage region in the chromosome of the B. cereus ATCC 10987 strain [11].…”
Section: Resultsmentioning
confidence: 99%
“…Research on about half of these proteins has been successfully completed, and results for some have been published [4][8], while research on the other half is still in progress. For those results that have been reported, 65% of proteins (44 of 68) have been verified to have the predicted function described in the COMBREX grant proposal, while no activity was observed for the remaining 24 (Table S1).…”
Section: Combrex Grants: Experiments Fundedmentioning
confidence: 99%